Online Education | Neuropsychotropic Drug Therapy 2017 - Decoding Psychotropic Black Box Warnings

Image for UW Adult/Geriatric Drug Therapy conference.
Decoding Psychotropic Black Box Warnings


This module illuminates the history and current trends in black box warnings on psychotropic medications, with a focus on new data and controversies surrounding the potential adverse effects of carbamazepine and varenicline. 



Jennifer Jepsen, PharmD, BCPS
Clinical Pharmacist, Pharmacy Department, Harborview Medical Center, Seattle


Comments and Reviews

"After hearing this talk, I will consider genetic testing before prescribing carbamazepine."


Target Audience

Nurse practitioners, clinical nurse specialists, nurses, pharmacists and other interested healthcare professionals.


Objectives for Learning Outcomes

At the conclusion of this activity, participants will be better able to:

  1. Revisit historical data that led to FDA Black Box labeling regarding antidepressants and suicidality.
  2. Review changes in antidepressant prescribing and rates of suicide attempts following antidepressant Black Box labeling.
  3. Summarize current data and controversy regarding antidepressant use and risk for increased suicidality.
  4. Describe HLA-B*1502 and identify patients that may benefit from genetic screening before use of carbamazepine.
  5. Outline data from the EAGLES study and impetus for reversal of labeling surrounding the adverse neuropsychotropic effects of varenicline.

Additional Information

Audio and Video
Course summary
Maximum credit available: 
  • 1.05 Contact hours
  • 1.05 Pharmacology hours at the advanced practice level

Available Credit

  • 1.05 Contact hours
  • 1.05 Pharmacology hours at the advanced practice level


Please login or create account to take this course.

Required Hardware/software

Adobe Acrobat Reader
Google Chrome, Firefox or Safari